GlassScriptPhysician profile
Grace S Kim
NPI 1679991897
$2,020.86
in general payments reported to CMS, 2019-2025
28 companies · $129 in 2025
The $129 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $37.04 · 2021: $275 · 2022: $180 · 2023: $342 · 2024: $880 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $770.03 | 2021-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $156.87 | 2021-2024 | Vaxelis, Gardasil 9, Proquad |
| Bayer Healthcare Pharmaceuticals INC. | $130.04 | 2023 | |
| Cranial Technologies, INC | $129.17 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $101.73 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.27 | 2021-2022 | |
| Novo Nordisk INC | $69.31 | 2019-2024 | Rybelsus, Ozempic |
| W. L. Gore & Associates, INC. | $66.70 | 2023 | Gore Tag Conformable Thoracic Endoprosthesis |
| Sanofi Pasteur INC. | $62.71 | 2019-2024 | |
| Genentech USA, INC. | $52.00 | 2019-2021 | |
| Pfizer INC. | $40.91 | 2022-2024 | |
| Dynavax Technologies Corporation | $32.76 | 2022-2024 | Heplisav-B |
| Corium, LLC | $29.03 | 2025 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $27.19 | 2022 | |
| Amgen INC. | $26.38 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.09 | 2021 | |
| Ironshore Pharmaceuticals INC. | $22.67 | 2023 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $22.40 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.39 | 2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $20.64 | 2023 | Flumist Quadrivalent |
| Esperion Therapeutics, INC. | $17.84 | 2021 | |
| Antares Pharma, INC. | $17.39 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.84 | 2024 | Unithroid |
| Ethicon US, LLC | $15.20 | 2022 | |
| Inspire Medical Systems, INC. | $13.95 | 2025 | Inspire |
| Amarin Pharma, INC. | $13.55 | 2019 | |
| Seqirus USA INC | $12.74 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Vistapharm, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.